Marion Laig of Thermo Fisher Scientific recently talked to us about how digital PCR helped confirm next generation sequencing results from cell free DNA samples (cfDNA).
Her poster, titled “Rare mutation analysis using Digital PCR on QuantStudio™ 3D to verify Ion AmpliSeq Next Generation Sequencing for Cancer Research” reveals how low frequency alleles can be detected using NGS and confirmed using digital PCR, assuring target confidence.
Next generation sequencing provides unparalleled sequencing information and is slowing becoming a tool for biomarker discovery in cancer research and for understanding tumor heterogeneity in samples. It is critical that targets be confirmed and called out confidently. This research sheds light on the sensitivity and accuracy of NGS to detect low frequency mutations and for digital PCR to provide robust confirmations on rare targets even in challenging samples like cfDNA.
Feel free to download your own copy of Marion’s poster on SlideShare and ask your questions in the comments section below.
Multiplex PCR Coupled with Fragment Analysis
A Hi-Plex Approach to Simultaneous Genomic Targets Detection...
Read More
Local, High-Quality NGS Can Improve SARS-CoV-2 Surveillance
A new preprint by Tegally et al.1 describes the rapid expans...
Read More
Variant Surveillance with Single-Day NGS
As SARS-CoV-2 continues to circulate and evolve, so too does...
Read More
Rapid, Highly Sensitive Mumps Genotyping with NGS
Despite widespread vaccination, the mumps virus is making a ...
Read More
Leave a Reply